| ［1］Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med,2012,366(23):2161-2170.［2］No authors listed. Streptomycin treatment of pulmonary tuberculosis.A medical research council investigation.Br Med J, 1948,2(4582):769-782. ［3］Gandotra S, Schnappinger D, Monteleone M,et al. In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nat Med, 2007,13(12):1515-1520.［4］MacMicking JD. M. tuberculosis passes the litmus test. Nat Med,2008,14(8):809-810. ［5］Demartino GN, Gillette TG. Proteasomes: machines for all reasons. Cell,2007,129(4), 659-662. ［6］Darwin KH, Ehrt S, Gutierrez-Ramos JC,et al.The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science,2003,302(5652), 1963-1966. ［7］Gill WP, Harik NS, Whiddon MR, et al. A replication clock for Mycobacterium tuberculosis. Nat Med, 2009,15(2):211-214.［8］Dye C, Scheele S, Dolin P,et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA,1999,282(7):677-686.［9］Lonnroth K, Castro KG, Chakaya JM, et al. Tuberculosis control and elimination 2010-50: cure, care, and social deve-lopment. Lancet,2010,375(9728):1814-1829.［10］Dye C, Williams BG. The population dynamics and control of tuberculosis. Science,2010,328(5980):856-861.［11］中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007—2008年).北京：人民卫生出版社，2010.［12］Zhao YL, Liu YH, Jiang GL,et al.Variations in quality of carbol fuchsin stains collected from routine tuberculosis laboratories. Int J Tuberc Lung Dis, 2009,13(1):126-129. ［13］World Health Organization.Diagnostics for tuberculosis: Global demand and market potential. Geneva: World Health Organization,2006.［14］World Health Organization.Pathways to better diagnostics for tuberculosis. Geneva: World Health Organization,2010.［15］Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med, 2010,363(11):1005-1015.［16］郄霜，张立，戴振华，等. 结核分枝杆菌融合抗原38F和64F诊断活动性肺结核的价值.中国防痨杂志，2013，35（9）：643-648.［17］袁小亮，张天托，朱家馨，等. 江西地区结核分枝杆菌耐二线抗结核药的分子学特征. 中国防痨杂志，2013，35（9）：649-654.［18］王晓平,逄宇,赵晓,等. 宁夏地区结核分枝杆菌基因分型及与耐药性关系的研究. 中国防痨杂志，2013，35（9）：655-659.［19］王婷,赵雁林,刘家云,等. 结核性脑膜炎临床分离株基因型和耐药表型的特征分析. 中国防痨杂志，2013，35（9）：660-667.［20］汪晓艳,赵雁林,逄宇,等. 重庆市结核分枝杆菌临床分离株的基因分型及相关耐药性分析. 中国防痨杂志，2013，35（9）：668-672.［21］蓝如束,蓝兰,黄曙海,等. 广西壮族自治区涂阳肺结核患者的耐药性分析. 中国防痨杂志，2013，35（9）：673-678.［22］段安虎,张薇,柏银兰,等. 结核分枝杆菌休眠相关抗原Rv1733c DNA疫苗的构建及免疫学特性研究. 中国防痨杂志，2013，35（9）：679-685.［23］王桂荣,付育红,梁倩,等. 应用多重PCR方法快速鉴定结核分枝杆菌复合群与非结核分枝杆菌的研究. 中国防痨杂志，2013，35（9）：686-689.［24］邝小佳,谭守勇,吴碧彤,等. 39株对克拉霉素耐药的结核分枝杆菌临床株23S rRNA检测结果分析. 中国防痨杂志，2013，35（9）：690-692.［25］李强,赵冰,夏辉,等. 结核分枝杆菌特异性蛋白（TB-SA）抗体检测试剂在结核病诊断中的应用研究. 中国防痨杂志，2013，35（9）：693-696.［26］车南颖,李雪莲,张旭霞,等. 40例肺结核患者病情进展中白细胞介素-8表达变化的初步研究. 中国防痨杂志，2013，35（9）：697-701.［27］李成行,李月翠. 检测内毒素与C反应蛋白在诊断肺结核合并革兰阴性菌感染中的意义. 中国防痨杂志，2013，35（9）：702-705.［28］Lathem WW, Price PA, Miller VL,et al. A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science, 2007,315(5811):509-513.［29］Keshavjee S, Farmer PE.Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med, 2012,367(10):931-936. ［30］Wares DF, Akhtar M, Singh S. DOT for patients with limited access to health care facilities in a hill district of eastern Nepal. Int J Tuberc Lung Dis,2001,5(8):732-740. |
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.
